A Phase 1, Two-Arm, Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2015
At a glance
- Drugs E 7974 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 17 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 17 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2009 Trial sponsor changed from Eisai Medical Research to Eisai Inc as reported by ClinicalTrials.gov